NYMC Faculty Publications
Oncolytic Virus in Gliomas: A Review of Human Clinical Investigations
Author Type(s)
Faculty
DOI
10.1016/j.annonc.2021.03.197
Journal Title
Annals of Oncology
First Page
968
Last Page
982
Document Type
Article
Publication Date
8-2021
Department
Neurosurgery
Abstract
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.
Recommended Citation
Carpenter, A. B., Carpenter, A. M., Aiken, R., & Hanft, S. (2021). Oncolytic Virus in Gliomas: A Review of Human Clinical Investigations. Annals of Oncology, 32 (8), 968-982. https://doi.org/10.1016/j.annonc.2021.03.197
